Urogen Pharma Ltd (NASDAQ:URGN) Q3 2023 Earnings Conference Call November 14, 2023 10:00 AM ET

Company Participants

Vincent Perrone - Senior Director, IR

Elizabeth Barrett - President, CEO & Director

Mark Schoenberg - Chief Medical Officer

Dong Kim - CFO

Jeffrey Bova - Chief Commercial Officer

Conference Call Participants

Leland Gershell - Oppenheimer

Raghuram Selvaraju - H.C. Wainwright & Co.

Boris Peaker - TD Cowen

Paul Choi - Goldman Sachs Group

Operator

Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations. You may begin.

Vincent Perrone

Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's Third Quarter 2023 Financial Results and Business Update Con Call. Earlier this morning, we issued our third quarter press release and filed our 10-Q where you can find details for our financial and operating results. Both documents can be accessed on the Investors portion of our site at investors.urogen.com.

Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Dr. Mark Schoenberg, Chief Medical Officer; Jeff Bova, Chief Commercial Officer; and Don Kim, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing commercialization activities related to JELMYTO, our ongoing and planned clinical trials; commercial and clinical milestones; market and revenue opportunities; our commercial strategy and expectation as well as potential future commercialization activities for UGN-102, if approved; anticipated data; regulatory filings and decisions including UGN-102, potentially receiving priority review. UGN-102 being the growth driver for UroGen, if approved; future research and development efforts; our corporate goals and 2023 financial guidance, among other things.

These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and UroGen disclaims any obligation to update these statements.

I'll now turn the call over to Liz. Liz?

Elizabeth Barrett

Thank you, Vincent, and welcome to everyone joining us today.

Before we remark on the quarter, I must mention the October 7 attack in Israel and its impact on our Israeli colleagues, partners and investors. The safety of our employees is and will continue to be top of mind. With regard to any potential impact to our business operations, I want to assure our shareholders that while we have a portion of our workforce based in Israel, we have robust contingency plans and international partnerships in place to sure the continued smooth operation of our business. As a result, we do not anticipate any significant impact on our business or operation. Finally, we hope and pray for Peace to return to the region as soon as possible.